Sonia Flores
Concepts (375)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Simian Acquired Immunodeficiency Syndrome | 7 | 2017 | 69 | 1.870 |
Why?
| HIV-1 | 10 | 2020 | 771 | 1.540 |
Why?
| Hypertension, Pulmonary | 12 | 2017 | 1754 | 1.420 |
Why?
| Lung | 17 | 2020 | 3673 | 1.250 |
Why?
| Antimicrobial Cationic Peptides | 3 | 2020 | 76 | 1.100 |
Why?
| Oxidative Stress | 11 | 2017 | 1093 | 1.090 |
Why?
| nef Gene Products, Human Immunodeficiency Virus | 6 | 2014 | 20 | 1.020 |
Why?
| Simian Immunodeficiency Virus | 6 | 2017 | 71 | 1.010 |
Why?
| Endothelium, Vascular | 7 | 2011 | 847 | 0.910 |
Why?
| HIV Infections | 14 | 2020 | 2474 | 0.880 |
Why?
| Macaca mulatta | 3 | 2017 | 132 | 0.760 |
Why?
| Gene Products, tat | 3 | 2011 | 19 | 0.690 |
Why?
| Gene Products, nef | 3 | 2009 | 13 | 0.680 |
Why?
| Superoxide Dismutase | 10 | 2005 | 332 | 0.660 |
Why?
| Nontuberculous Mycobacteria | 2 | 2020 | 207 | 0.570 |
Why?
| Macaca | 5 | 2011 | 51 | 0.570 |
Why?
| Cardiomegaly | 1 | 2017 | 161 | 0.560 |
Why?
| Microbiota | 4 | 2017 | 653 | 0.540 |
Why?
| Vascular Remodeling | 1 | 2017 | 155 | 0.530 |
Why?
| Pulmonary Artery | 6 | 2020 | 1037 | 0.500 |
Why?
| Calcifediol | 1 | 2014 | 29 | 0.470 |
Why?
| Calcitriol | 1 | 2014 | 53 | 0.450 |
Why?
| Golgi Apparatus | 2 | 2011 | 91 | 0.420 |
Why?
| Lipid Metabolism | 1 | 2015 | 449 | 0.400 |
Why?
| Cytokines | 3 | 2017 | 1853 | 0.400 |
Why?
| Diabetic Angiopathies | 3 | 2011 | 244 | 0.400 |
Why?
| Lipids | 1 | 2015 | 588 | 0.380 |
Why?
| Viral Regulatory and Accessory Proteins | 2 | 2012 | 27 | 0.370 |
Why?
| Carotid Artery Diseases | 1 | 2011 | 58 | 0.370 |
Why?
| Diabetes Mellitus, Type 1 | 6 | 2011 | 3256 | 0.360 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 221 | 0.360 |
Why?
| Developed Countries | 1 | 2010 | 29 | 0.350 |
Why?
| Diabetes Mellitus, Experimental | 2 | 2011 | 161 | 0.350 |
Why?
| Anti-HIV Agents | 3 | 2020 | 669 | 0.350 |
Why?
| Gene Expression Regulation, Viral | 2 | 2014 | 80 | 0.340 |
Why?
| Animals | 31 | 2020 | 32104 | 0.330 |
Why?
| DNA, Circular | 4 | 1990 | 13 | 0.330 |
Why?
| Sp1 Transcription Factor | 2 | 2005 | 23 | 0.300 |
Why?
| Cathelicidins | 3 | 2020 | 39 | 0.290 |
Why?
| Vascular Diseases | 1 | 2009 | 230 | 0.270 |
Why?
| Pulmonary Emphysema | 2 | 2016 | 316 | 0.270 |
Why?
| HIV | 2 | 2017 | 209 | 0.270 |
Why?
| T-Lymphocytes | 3 | 2011 | 1756 | 0.260 |
Why?
| Prostaglandins | 1 | 2005 | 78 | 0.260 |
Why?
| Bronchoalveolar Lavage Fluid | 4 | 2015 | 608 | 0.250 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 31 | 0.240 |
Why?
| Hyperglycemia | 1 | 2008 | 295 | 0.240 |
Why?
| Chemokines, CXC | 1 | 2004 | 58 | 0.240 |
Why?
| Atherosclerosis | 1 | 2008 | 342 | 0.240 |
Why?
| Autoimmune Diseases | 1 | 2007 | 395 | 0.230 |
Why?
| Lung Diseases | 3 | 2017 | 710 | 0.230 |
Why?
| Virus Replication | 4 | 2012 | 396 | 0.220 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 350 | 0.210 |
Why?
| Aspartic Acid | 1 | 2003 | 79 | 0.210 |
Why?
| Prediabetic State | 1 | 2005 | 225 | 0.210 |
Why?
| Smoking | 2 | 2013 | 1457 | 0.210 |
Why?
| Vasodilation | 1 | 2005 | 412 | 0.210 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 104 | 0.210 |
Why?
| Disease Models, Animal | 7 | 2020 | 3580 | 0.210 |
Why?
| Autoimmunity | 1 | 2008 | 822 | 0.200 |
Why?
| NADPH Oxidases | 4 | 2007 | 122 | 0.200 |
Why?
| Endothelium | 3 | 2014 | 115 | 0.200 |
Why?
| Humans | 37 | 2021 | 115741 | 0.200 |
Why?
| Nitric Oxide | 4 | 2011 | 832 | 0.190 |
Why?
| Cohort Studies | 7 | 2020 | 4949 | 0.190 |
Why?
| Plasmids | 6 | 2005 | 345 | 0.180 |
Why?
| Viral Tropism | 1 | 2020 | 24 | 0.180 |
Why?
| Arachidonate 5-Lipoxygenase | 1 | 2020 | 45 | 0.180 |
Why?
| Repetitive Sequences, Nucleic Acid | 3 | 1990 | 104 | 0.170 |
Why?
| Mice | 15 | 2013 | 15052 | 0.170 |
Why?
| Immune Evasion | 1 | 2020 | 47 | 0.170 |
Why?
| Fluorescent Antibody Technique | 3 | 2015 | 398 | 0.170 |
Why?
| Hospital Medicine | 1 | 2021 | 82 | 0.170 |
Why?
| Male | 21 | 2021 | 56050 | 0.170 |
Why?
| Membrane Lipids | 1 | 2020 | 87 | 0.170 |
Why?
| Career Choice | 1 | 2021 | 183 | 0.160 |
Why?
| Mice, Inbred NOD | 4 | 2011 | 560 | 0.160 |
Why?
| Phospholipids | 1 | 2020 | 202 | 0.160 |
Why?
| Mouth | 2 | 2015 | 67 | 0.160 |
Why?
| Apoptosis | 2 | 2007 | 2377 | 0.150 |
Why?
| Histocytochemistry | 1 | 2017 | 78 | 0.150 |
Why?
| DNA-Binding Proteins | 1 | 2004 | 1316 | 0.150 |
Why?
| CD4 Lymphocyte Count | 3 | 2016 | 257 | 0.140 |
Why?
| Education, Medical, Graduate | 1 | 2021 | 376 | 0.140 |
Why?
| Immunophenotyping | 1 | 2017 | 277 | 0.140 |
Why?
| Case-Control Studies | 3 | 2015 | 3037 | 0.140 |
Why?
| Transcription Factors | 1 | 2004 | 1528 | 0.140 |
Why?
| Financing, Government | 1 | 2016 | 40 | 0.130 |
Why?
| Plasma | 1 | 2017 | 213 | 0.130 |
Why?
| Mice, Inbred C57BL | 9 | 2013 | 4773 | 0.130 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 95 | 0.130 |
Why?
| Education | 1 | 2016 | 99 | 0.130 |
Why?
| Blotting, Western | 4 | 2005 | 1153 | 0.120 |
Why?
| Hydrogen Peroxide | 2 | 2007 | 287 | 0.120 |
Why?
| Clinical Competence | 1 | 2021 | 912 | 0.120 |
Why?
| Research Personnel | 1 | 2016 | 153 | 0.120 |
Why?
| Drug Resistance, Bacterial | 1 | 2015 | 156 | 0.120 |
Why?
| Female | 14 | 2021 | 60018 | 0.120 |
Why?
| Microbial Sensitivity Tests | 1 | 2015 | 299 | 0.120 |
Why?
| Cell Nucleus | 2 | 2009 | 553 | 0.110 |
Why?
| NF-kappa B | 2 | 2011 | 639 | 0.110 |
Why?
| Tyrosine | 2 | 2005 | 219 | 0.110 |
Why?
| Intracellular Space | 1 | 2014 | 68 | 0.110 |
Why?
| Tropheryma | 1 | 2013 | 4 | 0.110 |
Why?
| Whipple Disease | 1 | 2013 | 5 | 0.110 |
Why?
| Endothelial Cells | 4 | 2020 | 696 | 0.110 |
Why?
| Biota | 1 | 2013 | 35 | 0.110 |
Why?
| Phylogeny | 2 | 2020 | 805 | 0.110 |
Why?
| Mice, Transgenic | 3 | 2014 | 1970 | 0.110 |
Why?
| Inflammation | 4 | 2013 | 2500 | 0.110 |
Why?
| Physicians | 1 | 2021 | 776 | 0.110 |
Why?
| Pulmonary Fibrosis | 1 | 2016 | 330 | 0.110 |
Why?
| Pandemics | 1 | 2021 | 1335 | 0.110 |
Why?
| Global Health | 2 | 2017 | 290 | 0.110 |
Why?
| Pulmonary Medicine | 1 | 2014 | 88 | 0.110 |
Why?
| Immunohistochemistry | 2 | 2007 | 1642 | 0.100 |
Why?
| Metagenome | 1 | 2013 | 122 | 0.100 |
Why?
| Reperfusion Injury | 2 | 2005 | 254 | 0.100 |
Why?
| Molecular Sequence Data | 3 | 2013 | 2790 | 0.100 |
Why?
| San Francisco | 1 | 2012 | 56 | 0.100 |
Why?
| tat Gene Products, Human Immunodeficiency Virus | 3 | 2011 | 20 | 0.100 |
Why?
| Mice, SCID | 2 | 2011 | 321 | 0.100 |
Why?
| Respiratory System | 1 | 2013 | 141 | 0.100 |
Why?
| Dysbiosis | 1 | 2013 | 146 | 0.100 |
Why?
| Mucin-5B | 1 | 2013 | 185 | 0.100 |
Why?
| Respiratory Mucosa | 1 | 2013 | 258 | 0.100 |
Why?
| Rats | 4 | 2020 | 5033 | 0.100 |
Why?
| Odds Ratio | 1 | 2014 | 962 | 0.100 |
Why?
| Gastrointestinal Tract | 1 | 2013 | 168 | 0.100 |
Why?
| Gene Expression Profiling | 1 | 2017 | 1537 | 0.090 |
Why?
| Neointima | 1 | 2011 | 13 | 0.090 |
Why?
| Liver | 4 | 2005 | 1690 | 0.090 |
Why?
| Adoptive Transfer | 1 | 2011 | 199 | 0.090 |
Why?
| Gene Transfer Techniques | 1 | 2011 | 148 | 0.090 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2015 | 337 | 0.090 |
Why?
| Rats, Sprague-Dawley | 3 | 2004 | 2262 | 0.090 |
Why?
| Biomedical Research | 1 | 2016 | 589 | 0.090 |
Why?
| Oxygen | 2 | 2005 | 837 | 0.090 |
Why?
| DNA, Satellite | 1 | 1990 | 16 | 0.090 |
Why?
| Exodeoxyribonucleases | 1 | 1990 | 24 | 0.090 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2015 | 693 | 0.090 |
Why?
| Vascular Resistance | 2 | 2009 | 338 | 0.080 |
Why?
| Spleen | 1 | 2011 | 492 | 0.080 |
Why?
| Anti-Retroviral Agents | 1 | 2011 | 207 | 0.080 |
Why?
| Gene Expression Regulation, Enzymologic | 3 | 2005 | 274 | 0.080 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2015 | 965 | 0.080 |
Why?
| Adult | 6 | 2020 | 30789 | 0.080 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2009 | 503 | 0.080 |
Why?
| Eisenmenger Complex | 1 | 2008 | 10 | 0.080 |
Why?
| Transfection | 3 | 2005 | 866 | 0.080 |
Why?
| Luciferases | 2 | 2005 | 140 | 0.070 |
Why?
| Cell Line | 4 | 2011 | 2651 | 0.070 |
Why?
| Cross-Sectional Studies | 2 | 2016 | 4448 | 0.070 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 249 | 0.070 |
Why?
| Bacteria | 1 | 2013 | 729 | 0.070 |
Why?
| Minority Groups | 2 | 2021 | 230 | 0.070 |
Why?
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2007 | 48 | 0.070 |
Why?
| Hypertrophy | 1 | 2007 | 110 | 0.070 |
Why?
| Middle Aged | 6 | 2020 | 27069 | 0.070 |
Why?
| Reactive Oxygen Species | 1 | 2009 | 549 | 0.070 |
Why?
| Molecular Mimicry | 2 | 2003 | 35 | 0.070 |
Why?
| Bone Morphogenetic Proteins | 1 | 2007 | 133 | 0.070 |
Why?
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2005 | 3 | 0.070 |
Why?
| Acetophenones | 1 | 2005 | 14 | 0.070 |
Why?
| Onium Compounds | 1 | 2005 | 11 | 0.070 |
Why?
| Anti-Bacterial Agents | 1 | 2015 | 1485 | 0.070 |
Why?
| Enzyme Activation | 2 | 2004 | 793 | 0.060 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 58 | 0.060 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2005 | 72 | 0.060 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2008 | 342 | 0.060 |
Why?
| Oxidation-Reduction | 2 | 2005 | 924 | 0.060 |
Why?
| Macrophages, Alveolar | 2 | 2020 | 357 | 0.060 |
Why?
| Acetylcholine | 1 | 2005 | 180 | 0.060 |
Why?
| Sp3 Transcription Factor | 1 | 2004 | 6 | 0.060 |
Why?
| Chemokine CXCL1 | 1 | 2004 | 66 | 0.060 |
Why?
| Recombination, Genetic | 1 | 2005 | 177 | 0.060 |
Why?
| Collagen | 1 | 2007 | 416 | 0.060 |
Why?
| Phosphoric Monoester Hydrolases | 1 | 2005 | 54 | 0.060 |
Why?
| Blotting, Northern | 1 | 2004 | 194 | 0.060 |
Why?
| Cells, Cultured | 4 | 2020 | 3914 | 0.060 |
Why?
| Heart | 1 | 1988 | 610 | 0.060 |
Why?
| Free Radicals | 1 | 2004 | 98 | 0.060 |
Why?
| Nitric Oxide Synthase | 1 | 2005 | 213 | 0.060 |
Why?
| Ischemia | 2 | 2005 | 363 | 0.060 |
Why?
| Kupffer Cells | 1 | 2004 | 45 | 0.060 |
Why?
| Prevalence | 1 | 2010 | 2269 | 0.060 |
Why?
| Inflammation Mediators | 1 | 2007 | 479 | 0.060 |
Why?
| Transcription Factor AP-1 | 1 | 2004 | 82 | 0.060 |
Why?
| Guanosine | 1 | 2003 | 39 | 0.060 |
Why?
| Cell Line, Tumor | 3 | 2005 | 2751 | 0.060 |
Why?
| Acetylcysteine | 1 | 2004 | 144 | 0.060 |
Why?
| Drosophila | 1 | 2004 | 132 | 0.050 |
Why?
| Membrane Proteins | 1 | 2009 | 1024 | 0.050 |
Why?
| Cell Hypoxia | 1 | 2004 | 220 | 0.050 |
Why?
| Superoxides | 1 | 2004 | 215 | 0.050 |
Why?
| Hepatocytes | 1 | 2004 | 197 | 0.050 |
Why?
| Neovascularization, Pathologic | 1 | 2005 | 283 | 0.050 |
Why?
| Risk Factors | 3 | 2016 | 8702 | 0.050 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2003 | 45 | 0.050 |
Why?
| HeLa Cells | 1 | 2004 | 567 | 0.050 |
Why?
| Models, Chemical | 1 | 2004 | 257 | 0.050 |
Why?
| Mice, Inbred BALB C | 1 | 2005 | 1168 | 0.050 |
Why?
| Aging | 2 | 1990 | 1632 | 0.050 |
Why?
| Aorta | 1 | 2005 | 397 | 0.050 |
Why?
| Tumor Suppressor Proteins | 1 | 2005 | 286 | 0.050 |
Why?
| Caspase Inhibitors | 1 | 2003 | 78 | 0.050 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2004 | 277 | 0.050 |
Why?
| Fibroblasts | 1 | 2007 | 839 | 0.050 |
Why?
| Hepacivirus | 1 | 2004 | 234 | 0.050 |
Why?
| Homeostasis | 1 | 2005 | 577 | 0.050 |
Why?
| Pyrroles | 1 | 2003 | 185 | 0.050 |
Why?
| DNA | 2 | 2004 | 1356 | 0.050 |
Why?
| Metalloporphyrins | 1 | 2002 | 106 | 0.050 |
Why?
| Binding Sites | 1 | 2004 | 1177 | 0.050 |
Why?
| Cell Proliferation | 1 | 2008 | 2194 | 0.050 |
Why?
| Angiogenesis Inhibitors | 1 | 2003 | 216 | 0.050 |
Why?
| Phosphoproteins | 1 | 2003 | 304 | 0.050 |
Why?
| Salaries and Fringe Benefits | 1 | 2021 | 53 | 0.050 |
Why?
| Rats, Transgenic | 1 | 2020 | 15 | 0.050 |
Why?
| Cell Membrane | 2 | 2020 | 683 | 0.050 |
Why?
| Indoles | 1 | 2003 | 309 | 0.050 |
Why?
| DNA, Bacterial | 2 | 2013 | 309 | 0.040 |
Why?
| Sequence Analysis, DNA | 2 | 2013 | 732 | 0.040 |
Why?
| Epithelial Cells | 1 | 2006 | 961 | 0.040 |
Why?
| Chromatography, Thin Layer | 1 | 2020 | 24 | 0.040 |
Why?
| HIV Envelope Protein gp120 | 1 | 2020 | 56 | 0.040 |
Why?
| Macrophages | 2 | 2020 | 1284 | 0.040 |
Why?
| THP-1 Cells | 1 | 2020 | 20 | 0.040 |
Why?
| Receptors, CXCR4 | 1 | 2020 | 78 | 0.040 |
Why?
| Coloring Agents | 2 | 2014 | 71 | 0.040 |
Why?
| Pulmonary Alveoli | 1 | 2003 | 376 | 0.040 |
Why?
| Recombinant Fusion Proteins | 1 | 2003 | 616 | 0.040 |
Why?
| Rats, Inbred F344 | 1 | 2020 | 245 | 0.040 |
Why?
| Transcriptional Activation | 3 | 2009 | 340 | 0.040 |
Why?
| Mitochondria | 1 | 2005 | 750 | 0.040 |
Why?
| Biomarkers | 2 | 2015 | 3471 | 0.040 |
Why?
| Virulence | 1 | 2020 | 231 | 0.040 |
Why?
| Protein Binding | 1 | 2004 | 1917 | 0.040 |
Why?
| Disease Progression | 1 | 2005 | 2423 | 0.040 |
Why?
| Species Specificity | 1 | 2020 | 552 | 0.040 |
Why?
| Faculty, Medical | 1 | 2021 | 234 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2021 | 414 | 0.040 |
Why?
| Leadership | 1 | 2021 | 302 | 0.040 |
Why?
| Nitric Oxide Synthase Type III | 2 | 2011 | 185 | 0.040 |
Why?
| Cell Differentiation | 1 | 2004 | 1700 | 0.040 |
Why?
| Pneumonia | 1 | 2003 | 576 | 0.040 |
Why?
| Models, Biological | 3 | 2013 | 1646 | 0.040 |
Why?
| Phenotype | 2 | 2020 | 2839 | 0.030 |
Why?
| Escherichia coli | 1 | 2020 | 730 | 0.030 |
Why?
| Morbidity | 1 | 2017 | 278 | 0.030 |
Why?
| Promoter Regions, Genetic | 3 | 2005 | 1122 | 0.030 |
Why?
| Genotype | 1 | 2020 | 1787 | 0.030 |
Why?
| HIV Antigens | 1 | 2015 | 17 | 0.030 |
Why?
| Jurkat Cells | 1 | 2014 | 128 | 0.030 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 257 | 0.030 |
Why?
| Nanotubes | 1 | 2014 | 41 | 0.030 |
Why?
| Mucin 5AC | 1 | 2013 | 48 | 0.030 |
Why?
| DNA, Ribosomal | 1 | 2013 | 80 | 0.030 |
Why?
| Ear, Middle | 1 | 2013 | 89 | 0.030 |
Why?
| Myocardium | 2 | 1990 | 926 | 0.030 |
Why?
| Bronchoalveolar Lavage | 1 | 2013 | 89 | 0.030 |
Why?
| Prospective Studies | 2 | 2015 | 6276 | 0.030 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2015 | 193 | 0.030 |
Why?
| Survival Rate | 1 | 2017 | 1651 | 0.030 |
Why?
| Signal Transduction | 3 | 2014 | 4541 | 0.030 |
Why?
| Cilia | 1 | 2013 | 162 | 0.030 |
Why?
| Cell Death | 1 | 2014 | 326 | 0.030 |
Why?
| Cell Communication | 1 | 2014 | 282 | 0.030 |
Why?
| Congresses as Topic | 1 | 2014 | 204 | 0.030 |
Why?
| Phagocytosis | 1 | 2013 | 355 | 0.020 |
Why?
| Bacterial Infections | 1 | 2013 | 222 | 0.020 |
Why?
| Reference Values | 1 | 2013 | 750 | 0.020 |
Why?
| Sequence Analysis, Protein | 1 | 2011 | 29 | 0.020 |
Why?
| Flow Cytometry | 1 | 2015 | 1083 | 0.020 |
Why?
| RNA, Ribosomal, 16S | 1 | 2013 | 489 | 0.020 |
Why?
| Feces | 1 | 2013 | 372 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2015 | 1057 | 0.020 |
Why?
| Free Radical Scavengers | 1 | 2011 | 82 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 1219 | 0.020 |
Why?
| Multicenter Studies as Topic | 1 | 2011 | 249 | 0.020 |
Why?
| AIDS-Related Opportunistic Infections | 1 | 2011 | 117 | 0.020 |
Why?
| Centrifugation, Density Gradient | 1 | 1990 | 41 | 0.020 |
Why?
| Genetic Markers | 1 | 2011 | 325 | 0.020 |
Why?
| Staphylococcus aureus | 1 | 2013 | 385 | 0.020 |
Why?
| Protein Multimerization | 1 | 2011 | 160 | 0.020 |
Why?
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 191 | 0.020 |
Why?
| DNA Probes | 1 | 1990 | 59 | 0.020 |
Why?
| Protein Transport | 1 | 2011 | 400 | 0.020 |
Why?
| Chemokines, CX3C | 1 | 2009 | 10 | 0.020 |
Why?
| Nucleic Acid Hybridization | 1 | 1990 | 189 | 0.020 |
Why?
| Chemokine CCL5 | 1 | 2009 | 46 | 0.020 |
Why?
| Immunoblotting | 1 | 1990 | 281 | 0.020 |
Why?
| Organ Specificity | 1 | 1990 | 273 | 0.020 |
Why?
| NFATC Transcription Factors | 1 | 2009 | 76 | 0.020 |
Why?
| Active Transport, Cell Nucleus | 1 | 2009 | 111 | 0.020 |
Why?
| Down-Regulation | 1 | 2011 | 601 | 0.020 |
Why?
| Capillary Permeability | 1 | 2009 | 138 | 0.020 |
Why?
| Nucleic Acid Renaturation | 1 | 1988 | 7 | 0.020 |
Why?
| Microtubules | 1 | 2011 | 238 | 0.020 |
Why?
| Scleroderma, Systemic | 1 | 2009 | 96 | 0.020 |
Why?
| Nucleic Acid Denaturation | 1 | 1988 | 31 | 0.020 |
Why?
| Echocardiography | 1 | 2011 | 562 | 0.020 |
Why?
| Electrocardiography | 1 | 2011 | 564 | 0.020 |
Why?
| Cattle | 1 | 2011 | 935 | 0.020 |
Why?
| Genes | 1 | 1988 | 224 | 0.020 |
Why?
| Cardiac Catheterization | 1 | 2011 | 538 | 0.020 |
Why?
| Brain | 2 | 1990 | 2373 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2009 | 544 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 941 | 0.020 |
Why?
| DNA Transposable Elements | 1 | 1987 | 100 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2013 | 2420 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2016 | 2393 | 0.020 |
Why?
| Antioxidants | 1 | 2009 | 533 | 0.020 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1098 | 0.020 |
Why?
| beta-Galactosidase | 1 | 2005 | 63 | 0.020 |
Why?
| Fluoresceins | 1 | 2005 | 46 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2005 | 133 | 0.020 |
Why?
| Chick Embryo | 1 | 2005 | 122 | 0.020 |
Why?
| Phosphatidylinositol Phosphates | 1 | 2005 | 38 | 0.020 |
Why?
| Catalase | 1 | 2005 | 118 | 0.020 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2005 | 160 | 0.010 |
Why?
| Digitonin | 1 | 2004 | 4 | 0.010 |
Why?
| Genes, Reporter | 1 | 2005 | 257 | 0.010 |
Why?
| Replicon | 1 | 2004 | 15 | 0.010 |
Why?
| Survival | 1 | 2004 | 37 | 0.010 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2004 | 47 | 0.010 |
Why?
| Time Factors | 2 | 2005 | 6171 | 0.010 |
Why?
| Arachidonic Acids | 1 | 2003 | 58 | 0.010 |
Why?
| PTEN Phosphohydrolase | 1 | 2005 | 142 | 0.010 |
Why?
| Microscopy, Confocal | 1 | 2005 | 299 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 146 | 0.010 |
Why?
| Viral Nonstructural Proteins | 1 | 2004 | 56 | 0.010 |
Why?
| Carcinoma, Hepatocellular | 1 | 2005 | 224 | 0.010 |
Why?
| Carrageenan | 1 | 2003 | 6 | 0.010 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 263 | 0.010 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 128 | 0.010 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 332 | 0.010 |
Why?
| Hypoxia | 1 | 2009 | 937 | 0.010 |
Why?
| I-kappa B Proteins | 1 | 2003 | 78 | 0.010 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 400 | 0.010 |
Why?
| Transcription Factor RelA | 1 | 2003 | 83 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2005 | 804 | 0.010 |
Why?
| Respiratory Burst | 1 | 2002 | 28 | 0.010 |
Why?
| Edema | 1 | 2003 | 119 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 6423 | 0.010 |
Why?
| Insulinoma | 1 | 2002 | 29 | 0.010 |
Why?
| Extremities | 1 | 2003 | 113 | 0.010 |
Why?
| Antigen-Presenting Cells | 1 | 2002 | 153 | 0.010 |
Why?
| Clone Cells | 1 | 2002 | 248 | 0.010 |
Why?
| Cytotoxicity, Immunologic | 1 | 2002 | 198 | 0.010 |
Why?
| Heparin | 1 | 2003 | 227 | 0.010 |
Why?
| Proto-Oncogene Proteins | 1 | 2005 | 609 | 0.010 |
Why?
| Gene Rearrangement | 1 | 2002 | 135 | 0.010 |
Why?
| Liver Neoplasms | 1 | 2005 | 521 | 0.010 |
Why?
| Asthma | 1 | 2013 | 2066 | 0.010 |
Why?
| Mutation | 1 | 2011 | 3364 | 0.010 |
Why?
| Enzyme Inhibitors | 1 | 2004 | 757 | 0.010 |
Why?
| Cell Division | 1 | 2002 | 759 | 0.010 |
Why?
| United States | 1 | 2016 | 12304 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2005 | 1310 | 0.010 |
Why?
| Base Sequence | 1 | 2003 | 2114 | 0.010 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1137 | 0.010 |
Why?
| Phosphorylation | 1 | 2003 | 1571 | 0.010 |
Why?
| Antineoplastic Agents | 1 | 2009 | 1893 | 0.010 |
Why?
| Lipopolysaccharides | 1 | 2002 | 826 | 0.010 |
Why?
| Interferon-gamma | 1 | 2002 | 726 | 0.010 |
Why?
| Interleukin-1 | 1 | 2003 | 971 | 0.010 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2002 | 630 | 0.010 |
Why?
| Young Adult | 1 | 2013 | 10518 | 0.010 |
Why?
| RNA, Messenger | 1 | 2005 | 2574 | 0.010 |
Why?
| Islets of Langerhans | 1 | 2003 | 729 | 0.010 |
Why?
| Neutrophils | 1 | 2003 | 1172 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2003 | 2586 | 0.010 |
Why?
| Adolescent | 1 | 2013 | 17922 | 0.010 |
Why?
| Aged | 1 | 2013 | 19294 | 0.010 |
Why?
|
|
Flores's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|